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Abstract To understand the basic structural requirements for
the biological activity of endothelin peptides, the solution
structure of an ETB selective agonist, ET-1[Cys-(Acm)1;15,
Ala3,Leu7,Aib11], was investigated by 1H NMR spectroscopy
and molecular modelling. The structure is characterised by an
K-helical conformation between residues Ser5-His16 but is
undefined at both the N and C termini. To date, neither the
solution structures of linear modified peptides nor the effects of a
methanol/water solvent system have been examined for endothe-
lin or endothelin-like peptides. This structure plays an important
role towards the design of endothelin receptor selective agonists
and antagonists.
z 1998 Federation of European Biochemical Societies.
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1. Introduction
The endothelins are a family of bicyclic 21-amino acid pep-
tides. Endothelin-1 (ET-1) was ¢rst reported by Yanagisawa
et al. [1], and was shown to be the most potent known vaso-
constrictor. Subsequent studies have revealed more related
mammalian subtypes, namely ET-2, ET-3 and (VIC) ET-L
[2,3] as well as the reptilian sarafotoxins [4] isolated from
the venom of burrowing asps. ET-1, ET-2 and ET-3 all ap-
pear to be distinct gene products, and ET-L appears to be the
rat form of ET-2. Two major endothelin receptor subtypes,
ETA and ETB, which are categorised according to their rela-
tive a⁄nities, have been identi¢ed from bovine and rat lung
respectively [5,6]. Human ETA and ETB receptors have also
been cloned [7,8] and a third receptor subtype, ETC, has been
described [9]. The ETA receptor has a higher speci¢city for
ET-1 and ET-2 than for ET-3, and the ETB receptor has
approximately equal speci¢city for all the endothelins. These
peptide families produce numerous biological responses and
are implicated in a number of disease states on renal, cardio-
vascular, haemodynamics and endocrine function [10]. There
have been many reports of structure-activity relationship stud-
ies and pharmacological evaluations of endothelin analogues
and fragments [11^13]. The development of selective receptor
agonists and antagonists plays an important role in providing
therapeutic agents for the treatment of human diseases. To
determine the important structural features, many research
groups have studied solution conformations of endothelin
peptides which show potential activity. In this paper, we
present the solution structure of an endothelin B receptor
selective agonist, ET-1[Cys(Acm)1;15,Ala3,Leu7,Aib11] (Fig. 1)
determined by molecular modelling based on 1H nuclear mag-
netic resonance data.
2. Materials and methods
2.1. Peptide synthesis [14]
Peptide LJP2 was synthesised by solid phase Fmoc chemistry (0.25
mmol scale) on an adapted ABI 430A Peptide Synthesiser using Wang
resin as the solid supporter. All residues were incorporated by double-
coupling protocols using HOCt active esters. The only exception was
histidine which was coupled through its HOBt ester, due to increased
racemisation with its HOCt ester. In each cycle, one cartridge con-
taining 1.0 mmol Fmoc amino acid was used and the active ester was
formed via the addition of 0.5 mmol DIC. The amino acid sidechain
protections were: OtBu (Asp, Glu), tBu (Ser, Tyr), Boc (Lys), Trt
(His), Acm (Cys). The Fmoc group was deprotected with 20% piper-
idine in DMF. The deprotection was monitored by an on-line UV
system. Acetylation was carried out in a solution of 0.5 M acetic
anhydride, 0.125 M DIEA and 0.2% HOBt in DMF. On completion
of synthesis, the peptide was cleaved from the resin by treatment with
a mixture of TFA:EDT:thioanisole:TIS:H2O: (10:1:0.5:0.2:0.5).
The crude peptide was precipitated from ether after removing the
TFA in vacuo. The crude, fully reduced peptide was puri¢ed by a
C18 semi-preparative column eluted with a linear gradient of 0.1%
TFA/H2O and an increasing concentration of 0.1% TFA/CH3CN at
5 ml/min. The puri¢ed peptide, C117H178N27O34S2, was characterised
by electrospray MS ([MH] found = 2568.6; calc. = 2569.2) and by
di¡erent analytical HPLC conditions (RP C18, Vydac C18 and Hi-
chrom C18 columns). Amino acid analysis, after acid hydrolysis,
gave the correct molar ratios of the constituent amino acids.
2.2. NMR spectroscopy
All NMR experiments were performed using a 5 mm inverse probe-
head on a Varian VXR 600S NMR spectrometer operating at a 1H
resonance frequency of 599.945 MHz. The peptide sample (5 mg) was
dissolved in a 1:1 mixture of CD3OH and H2O (700 Wl) except for
amide proton exchange studies when the peptide sample was dissolved
in a 1:1 mixture of CD3OD and D2O. The NMR experiments were
carried out at 298 K except for studies where the e¡ects of temper-
ature were being monitored.
One-dimensional (1D) single pulse proton NMR spectra and two-
dimensional (2D) phase-sensitive DQFCOSY [15], TOCSY [16] and
NOESY [17] data sets were acquired with a presaturation delay of 1.5
s. An MLEV-17 ‘clean-tocsy’ spin-lock pulse sequence was applied for
a mixing time of 80 ms surrounded by two trim pulses of 2 ms each.
The NOESY data were acquired with a 150 ms mixing time. The
experiments were acquired with 32, 16 and 32 transients for each of
2U256 t1 increments (hypercomplex acquisition) [18] into 2048 com-
plex data points for the DQFCOSY, TOCSY and NOESY data re-
spectively. Other acquisition parameters for all three data sets were as
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follows: acquisition time, 0.146 s; spectral width, 7 kHz. Fourier
transformation in F2 was carried out without zero ¢lling whereas
data were zero ¢lled to 1024 data points in F1 prior to transforma-
tion. All the data sets were apodised in both dimensions using a
shifted squared sinebell window function. The real FT was carried
out on 1024U2048 data points. All the 2D spectra were acquired
on a non-spinning sample. Variable temperature studies of the peptide
sample (1 mg) were carried out using a standard 1D 1H NMR pulse
sequence. All spectra were referenced internally to the residual 1H
signal of CD2HOH resonating at 3.30 ppm. Data were acquired
and processed using the Varian VNMR software (Version 4.1).
2.3. Molecular modelling
Structure calculations were carried out using the Tripos molecular
modelling software SYBYL (Version 6.1) [19]. NMR data used for
structure calculations were imported into the TRIAD module of SYB-
YL. The NOESY data acquired with a mixing time of 150 ms were
used to derive interproton distances. NOEs were classi¢ed into three
categories of upper distance bounds according to their volume integral
values: 2.8 Aî (strong); 3.6 Aî (medium); 5.0 Aî (weak). The lower
distance bound was in all cases set to the van der Waals distance of
1.8 Aî . The threshold values of upper distance bounds were established
based on known sequential distances of dNN and dKN [20]. Pseudo-
atoms were introduced for protons which could not be stereospeci¢-
cally assigned [21]. Amide protons which showed slow exchange rates
from exchange studies were generally in the helical region of the pep-
tide backbone. These were used as constraints with the relevant back-
bone carbonyl interatomic distances by introducing hydrogen bonds
in the range 1.8^2.0 Aî (H-O) and 2.7^3.0 Aî (N-O) [22]. Torsional
angle constraints, which were generated from the 3JHNK coupling con-
stants (6 5.5 Hz), were applied in the 390‡ to 340‡ range.
Starting structures were built using SYBYL. The distance geometry
program DIANA [23] was used to generate random starting struc-
tures. The 208 distance constraints obtained from the NOESY
cross-peak volumes were used as input to DIANA. Eight constraints
for hydrogen bonds and nine torsional angle constraints were also
incorporated. During the DIANA calculation, atomic distances were
constrained using the force constant kNOE = 1 kcal mol31 Aî 32 and
torsions were constrained using kDihedc = 0.01 kcal mol
31 deg32. DI-
ANA was used to calculate 300 structures and the calculation pro-
duced 37 best structures along with 131 structurally important modi-
¢ed bounds. Output structures from the DIANA calculation were
then constrained by these modi¢ed distance bounds. In these struc-
tures, interatomic distances were constrained using a higher force
constant of kNOE = 10 kcal mol31 Aî 32. Torsions were constrained
using the same force constant. Structures were then subjected to 200
steps of conjugate-gradient energy minimisation.
Energy minimised structures were re¢ned using a dynamical simu-
lated annealing (DSA) protocol. DSA cycles proceeded with an an-
nealing step at a temperature of 1000 K for a period of 5400 fs
followed by an annealing period of 900 fs to a temperature of 100
K in a stepwise fashion. The Boltzmann scaling of atomic velocities
was chosen from a random number seed. Ten cycles of heating and
cooling were applied to each starting structure. The conformations
obtained by DSA were further minimised with 200 steps of conju-
gate-gradient energy minimisation. The energy minimised conforma-
tions were subjected to a ¢nal molecular dynamics (MD) quenching
calculation performed in the gas phase. The initial atomic velocities
were chosen from a random distribution at 1000 K and the dynamic
trajectory (100 fs) was followed for 20 ps in 1 fs steps. These calcu-
lations were carried out under NTV ensemble conditions with a 10 fs
temperature coupling factor. The molecular dynamics calculations
were repeated three times for each conformation using di¡erent ran-
dom number seed values. Each set of conformers was averaged to
obtain averaged conformations which were ¢nally subjected to 500
steps of conjugate-gradient energy minimisation after the removal of
all experimental energy barriers.
3. Results and discussion
Peptide LJP2 was synthesised in our laboratory using a
newly developed coupling reagent (HOCt) [14]. The coupling
percentage of Peptide LJP2 was greatly improved with this
new coupling reagent and the crude peptide was a¡orded in
very good purity according to HPLC analysis. Most of the
pharmacological evaluations in the ¢eld of endothelin re-
search have concentrated on endothelin and endothelin-like
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Table 1
1H chemical shiftsa obtained for Peptide LJP2 obtained in 1:1 aqueous methanol
NH KH LH QH NCH2 OCH2 Aromatics
KCH3 LCH3 QCH3 NCH3 OCH3 Others
1 C 4.30 3.16, 3.00
2 S 8.75 4.54 3.90, 3.98
3 A 8.66 4.28 1.43
4 S 8.24 4.30 3.85, 3.90
5 S 8.17 4.33 3.92, 4.00
6 L 8.01 4.16 1.66, 1.66 1.66 0.88, 0.93
7 L 7.93 4.16 1.60, 1.70 1.66 0.91, 0.87
8 D 8.06 4.47 2.96, 2.86
9 K 7.92 4.06 1.92, 1.60 1.43 1.65 2.93 +NH3 : 6.67, 6.70
10 E 8.11 4.06 2.17, 2.19 2.38, 2.59
11 Xb 8.14 1.54, 1.54
12 V 7.55 3.72 2.06 0.97, 0.82
13 Y 7.85 4.22 2.90, 2.90 2/6: 6.74, 3/5: 6.61
14 F 8.21 4.39 3.00, 3.25 2/6: 7.27, 3/5: 7.32
4H: 7.31
15 C 8.11 4.48 3.04, 3.04
16 H 8.12 4.57 3.32, 3.25 2H: 8.58, 4H: 7.27
17 L 7.86 4.26 1.60, 1.60 1.53 0.79, 0.79
18 D 8.30 4.62 2.75, 2.92
19 I 7.69 4.09 1.71 0.74 0.61
1.01, 1.36
20 I 7.86 4.15 1.76 0.80 0.79
1.08, 1.40
21 W 8.03 4.65 3.17, 3.28 2H: 7.15, 4H: 7.54
5H: 7.03, 6H: 7.10
7H: 7.35, NH: 10.08
aChemical shifts are referenced to the residual CD2HOH signal at 3.3 ppm.
bX, K-aminoisobutyric acid.
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compounds and their truncated analogues. In this study we
have concentrated on examining linear endothelin analogues
of ET-1 by modifying crucial cysteine residues. These were
replaced by either Ala or Aib (K-aminoisobutyric acid) resi-
dues. According to general peptide chemistry, Aib improves
the stability and solubility of the peptide chain. In this case we
made alterations to the inner disulphide bridge, replacing cys-
teine at position 3 by Ala and the other end of the disulphide
bridge at position 11 by Aib. The sidechains of the outer
disulphide bridge, Cys1 and Cys15, were protected by -CH2-
NH-CO-CH3 (Acm) groups. The methionine at position 7,
which is liable to oxidation, was replaced by leucine.
Peptide LJP2 displayed well resolved, sharp NMR signals
in the mixed solvent of aqueous methanol. The proton 1D
and DQFCOSY, TOCSY and NOESY 2D spectra were ac-
quired as described. Table 1 details the resonance assignments
deduced for Peptide LJP2 from these data. Almost all of the
amino acid spin systems could be distinguished from one an-
other in the TOCSY spectrum. Despite the low molecular
mass of this peptide, a large number of negative nOes were
observed in the 2D NOESY spectrum, which is a character-
istic normally associated with folded proteins. The AMX spin
systems, aromatics and multiple copies of the same amino
acids were carefully delineated using the NOESY spectrum.
The four aromatic residue spin systems were identi¢ed using
the NOESY connectivities between L-protons and their aro-
matic ring proton resonances. The individual identi¢cation of
aromatic resonance spin patterns were determined by direct
comparison of the TOCSY and NOESY spectra. Sequence-
speci¢c resonance assignments were completed with complete
identi¢cation of all the individual spin systems being simulta-
neously con¢rmed. Fig. 2 shows the sequential connectivity
delineation along the backbone. Fig. 3 illustrates the nOe
connectivities of Peptide LJP2. All the sidechain spin connec-
tivities through KH signals were clearly observed in the
TOCSY spectrum for all amino acid residues. Although
weak cross-peaks were observed for methyl resonances of
the K-aminoisobutyric acid, Aib11, in the TOCSY spectrum,
strong methyl resonances were observed in the NOESY spec-
trum. The dLN(i,i+1) and dNN(i,i+1) connectivities of neigh-
bouring amino acid residues supported the reliability of the
resonance assignments.
Evidence of secondary structure was obtained from long-
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Fig. 2. Fingerprint (HN-HK) region of the 1H 2D NOESY NMR
spectrum of Peptide LJP2 at a mixing time of 150 ms. The back-
bone ‘walk’ is indicated together with selected residue assignments.
Fig. 3. Summary of interresidue nOe connectivities observed for Peptide LJP2. The thickness of the columns and bars is proportional to the
nOe intensity. Broken bars represent overlapped nOe cross-peaks.
Fig. 1. Amino acid sequences of ET-1 and Peptide LJP2. The disul-
phide bridges of ET-1 are between C1-C15 and C3-C11. Underlined
residues are sites of di¡erences from ET-1. The cysteine sidechains
of Peptide LJP2 were protected by the -CH2-NH-CO-CH3 (Acm)
group. X denotes K-aminoisobutyric acid.
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range connectivities observed in the NOESY spectrum. The
¢ngerprint region of the NOESY spectrum showed clear
dKN(i,i+3) connectivities for S5/D8, K9/V12, V12/C15, F14/L17,
some overlapping cross-peaks for L6/K9, D8/X11 and weak
connectivities of E10/F14 and Y13/H16. The methyl resonance
of Aib11 also showed strong long-range connectivity to
F14NH. The aliphatic region of the NOESY spectrum showed
dKL(i,i+3) cross-peaks, S5/D8, L6/K9, L7/E10, D8/X11, K9/V12,
E10/Y13 and V12/C15, supporting evidence for an K-helical seg-
ment between S5-H16. The prominent connectivity patterns of
dKN(i,i+n), dNN(i,i+1) and dKL(i,i+3) con¢rmed the K-helical
character of Peptide LJP2. Small 3JNHK coupling constants
(V4 Hz) measured from the 1D 1H NMR spectrum were
also consistent with an K-helical character.
The temperature dependence of backbone amide proton
chemical shifts was measured over the temperature range
290^313 K. A structured state was apparent from the very
small temperature gradient of D8 vN/vT=30.7 ppb/C. Small
temperature coe⁄cients of 31.8 ppb/C for Y13 and 33.4 ppb/
C for K9 and H16 indicated shielding from solvent exchange
of the amide protons of residues between 9 and 16. This
suggested that amide protons in the helical region were in-
volved in hydrogen bonding. The remaining parts of Peptide
LJP2, especially the C-terminal region beyond H16, showed a
series of strong dKN(i,i+1) NOEs and larger 3JNHK coupling
constants for I19, I20 and W21 (V7 Hz).
These qualitative observations were combined with the re-
sults from the quantitative structure calculations describe ear-
lier. These structures clearly revealed the K-helical character
between residues 5 and 16. Fig. 4 shows a representative fam-
ily of 10 structures resulting from a combination of DIANA,
DSA and energy minimisation calculations. The ¢nal atomic
RMSD for all atoms in the helical region (residues 6^15) was
found to be 1.95 þ 0.32 Aî , compared to backbone only atoms
for which the ¢nal RMSD was found to be 0.63 þ 0.22 Aî . The
ordered sidechain groups adopted a stable conformation as
evidenced by numerous interresidue nOe constraints observed
for this region. It was possible to observe the extension of the
helix form one residue either side for some of the modelled
structures. This was clearly con¢rmed by weak long-range
cross-peaks observed in the NOESY spectrum.
NMR structures of ET-1 in aqueous media de¢ne the helical
structural region from Lys9 to Cys15 and in some cases this
has been shown to extend to Leu17 [24,25]. Peptides are nat-
urally formed in aqueous environments and water could there-
fore have been used as the NMR solvent in the present study.
By way of contrast, less polar solvents, such as methanol or
TFE, tend to induce more structure in peptides because of the
weaker capacity of the solvent to engage in hydrogen bonding
with the peptide. In our studies, water alone was found to
precipitate peptides of a similar sequence to that under inves-
tigation in the current study. A more suitable NMR solvent
was found to be a 1:1 mixture of CD3OH:H2O. This mixed
solvent system is frequently used in our laboratory for anal-
ysis by HPLC. Our studies of the solution structure of syn-
thetic ET-1 (synthesised in this laboratory) in the same mixed
solvent system showed the K-helix to lie between residues Lys9
and His16 [26]. Removal of the disulphide constraints and
introduction of the amino acid residues Ala and Aib lengthens
the K-helix by one turn compared to the K-helix of ET-1.
Contradictory reports exist of the conformation of the bio-
logically important C-terminal region of endothelin and endo-
thelin-related peptides, but most studies have been unable to
describe in detail the tail region. Our studies failed to reveal
any de¢ned structural features at either the N or C terminus.
This is re£ected in both the total atom RMSD for residues 1^
21 of 5.68 þ 1.20 Aî and the backbone atom RMSD for the
same residues of 4.04 þ 0.91 Aî . These ¢gures are consistent
with disordered N and C termini. The 3JNHK couplings meas-
ured for these regions of Peptide LJP2 were consistent with
conformational averaging. The H-D exchange studies of sim-
ilar peptides of the same length and with identical C-terminal
residues showed somewhat slower amide protons exchange
rates for the last three residues, I19, I20 and W21. This indi-
cates poor solvent accessibility to the amide protons in the tail
region. The calculated structures obtained for Peptide LJP2
remain within one family of conformations and the level of
agreement obtained between structures, especially in the heli-
FEBS 20006 27-3-98
Fig. 4. Stereoview of 10 superimposed solution structures of Peptide LJP2 based on the nOe data. The superimposition is shown as a best ¢t
of the backbone for residues 5^16.
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cal region, demonstrated the ordered conformation in which a
helical region, extending from Ser5 to His16, exists.
Numerous studies have been carried out using synthetic
analogues and fragments of endothelin with each portion of
the peptide being examined for its relative importance in re-
ceptor binding and functional activities. In general, full length
bicyclic analogues appear to be required for ETA binding
whilst linear and truncated analogues have proved to be
ETB receptor selective. The linear endothelin analogue ET-
1[1,3,11,15-Ala], in which all cysteines are replaced by ala-
nines, did not require the presence of the disulphide bridges
for binding to the rat cerebellum (ETB receptor) [27,28] but it
was functionally inactive in the rat aorta and mesenteric bed
(ETA receptor) [29].
In this study, Peptide LJP2, in which the inner disulphide
bridge positions 3 and 11 were replaced with Ala and Aib
respectively, shows potent agonist activity in the rat cerebel-
lum (ETB). The results observed for similar linear ET-1 ana-
logues suggest that the two disulphide bridges are critical for
ETA receptor binding but not for ETB receptor binding [30^
32]. Nakajima et al. [33] reported that the replacement in ET-1
of Met7 by Leu7 caused no loss in agonist activity in rat
pulmonary artery (ETB). In our studies, the linear ET-1 ana-
logues, synthesised by replacing the methionine at position 7
with norleucine or leucine, showed similar results for receptor
binding and functional activity [34]. However, with leucine at
position 7, the functional activity at the ETB receptor site was
slightly reduced for some analogues [34].
In conclusion we have shown, by NMR and molecular
modelling, that a synthetic linear modi¢ed derivative of the
ETB receptor binding peptide ET-1, namely Peptide LJP2
(ET-1[Cys(Acm)1;15,Ala3,Leu7,Aib11]), folds into an K-helix
in a 1:1 water/methanol mixed solvent solution. Our studies
also demonstrate that the disulphide bridges present in ET-1
are crucial neither for maintaining secondary structural fea-
tures nor for a¡ecting ETB receptor binding activity.
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